IBA to distribute Lantheus radiopharma products in Europe
Ion Beam Applications (IBA) has signed an agreement with Lantheus Medical Imaging of North Billerica, Mass., for the exclusive distribution of Cardiolite and Neurolite in several European countries, including France, Germany, United Kingdom and Spain.
The distribution agreement will take effect Sept. 1, and will show a neutral contribution to IBA’s bottom line in 2008, while it will increase profitability in 2009, according to the Louvain-la-Neuve, Belgium-based IBA. The company said that annual revenues expected from both products is over EUR 10 million; but it will decline in the coming years as new generic competitive products will be marketed.
Cardiolite is a kit for the preparation of Technetium Tc99m Sestamibi for Injection, used for myocardial perfusion imaging (commonly known as nuclear stress testing). Neurolite is a kit for the preparation of Technetium Tc99m Bicisate for Injection, used for brain scintigraphy.
The distribution agreement will take effect Sept. 1, and will show a neutral contribution to IBA’s bottom line in 2008, while it will increase profitability in 2009, according to the Louvain-la-Neuve, Belgium-based IBA. The company said that annual revenues expected from both products is over EUR 10 million; but it will decline in the coming years as new generic competitive products will be marketed.
Cardiolite is a kit for the preparation of Technetium Tc99m Sestamibi for Injection, used for myocardial perfusion imaging (commonly known as nuclear stress testing). Neurolite is a kit for the preparation of Technetium Tc99m Bicisate for Injection, used for brain scintigraphy.